Screener
Vir Biotechnology, Inc. VIR Business Segments — Clinical costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:ResearchAndDevelopmentClinicalCosts.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | ||||
| Contract manufacturing | 23,967 | 14,063 | 59,974 | 23,399 |
| Personnel (2) | 28,512 | 33,165 | 60,040 | 66,883 |
| Clinical costs | 22,532 | 20,361 | 48,666 | 40,967 |
| Licenses, collaborations and contingent consideration, net | 41,211 | 11,301 | 38,402 | 47,892 |
| Other R&D (3) | 19,061 | 18,619 | 37,123 | 37,013 |
| Selling, general and administrative (2) | 30,196 | 22,283 | 53,535 | 46,227 |
| Restructuring, long-lived assets impairment and related charges, net | — | (172) | — | (182) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s business segments — clinical costs?
- Vir Biotechnology, Inc. (VIR) reported business segments — clinical costs of $22.53M in Q2 2026.
- How has Vir Biotechnology, Inc.'s business segments — clinical costs changed year-over-year?
- Vir Biotechnology, Inc.'s business segments — clinical costs increased by 10.7% year-over-year, from $20.36M to $22.53M.
- What is the long-term trend for Vir Biotechnology, Inc.'s business segments — clinical costs?
- Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — clinical costs has grown at a -9.8% compound annual growth rate (CAGR), from $118.85M to $87.17M.
- What does business segments — clinical costs mean?
- Includes all direct expenditures related to conducting clinical trials, such as patient recruitment, site management, and data analysis for drug candidates. It is a critical measure of the investment intensity required to advance the company's pipeline through regulatory approval stages.
Ask your AI about Vir Biotechnology, Inc.'s business segments — clinical costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude